Granules India Limited (NSE:GRANULES)
565.60
-8.70 (-1.51%)
Oct 31, 2025, 3:30 PM IST
Granules India Revenue
Granules India had revenue of 12.10B INR in the quarter ending June 30, 2025, with 2.56% growth. This brings the company's revenue in the last twelve months to 45.12B, down -4.02% year-over-year. In the fiscal year ending March 31, 2025, Granules India had annual revenue of 44.82B, down -0.55%.
Revenue (ttm)
45.12B
Revenue Growth
-4.02%
P/S Ratio
3.04
Revenue / Employee
11.10M
Employees
4,066
Market Cap
137.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 44.82B | -247.59M | -0.55% |
| Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
| Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
| Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
| Mar 31, 2021 | 32.38B | 6.39B | 24.59% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 279.66B |
| Zydus Lifesciences | 236.08B |
| Apollo Hospitals Enterprise | 225.51B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Granules India News
- 2 months ago - Granules India Q1 Results: Revenue jumps 2.56% YoY to Rs 1,210.11 crore, net profit falls 16.37% YoY - Business Upturn
- 3 months ago - Granules India’s Hyderabad unit receives one US FDA observation after Pre-Approval Inspection - Business Upturn
- 3 months ago - Granules India CEO Kandiraju Venkata Sitaram Rao resigns, effective July 31 - Business Upturn
- 4 months ago - Granules India clears US FDA Pre-Approval Inspection with zero observations - Business Upturn
- 4 months ago - Granules India’s Bonthapally facility completes US FDA inspection with one observation - Business Upturn
- 4 months ago - Pharma scrips fall on Trump tariff threat - The Times of India
- 8 months ago - Granules India shares drop nearly 3% amid US FDA warning letter - Business Upturn
- 8 months ago - Granules India shares drop 3.6% after receiving US FDA warning letter for Gagillapur facility - Business Upturn